Geode Capital Management LLC Has $46.22 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Geode Capital Management LLC increased its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 5.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,482,051 shares of the specialty pharmaceutical company’s stock after buying an additional 74,438 shares during the quarter. Geode Capital Management LLC owned 2.68% of Supernus Pharmaceuticals worth $46,218,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Louisiana State Employees Retirement System raised its position in shares of Supernus Pharmaceuticals by 2.2% during the second quarter. Louisiana State Employees Retirement System now owns 27,700 shares of the specialty pharmaceutical company’s stock worth $741,000 after purchasing an additional 600 shares during the period. Bank of New York Mellon Corp raised its holdings in Supernus Pharmaceuticals by 0.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 425,387 shares of the specialty pharmaceutical company’s stock worth $11,379,000 after buying an additional 2,427 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Supernus Pharmaceuticals by 20.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,083 shares of the specialty pharmaceutical company’s stock valued at $350,000 after buying an additional 2,225 shares in the last quarter. Innealta Capital LLC acquired a new position in shares of Supernus Pharmaceuticals in the second quarter valued at approximately $51,000. Finally, Commonwealth Equity Services LLC increased its position in shares of Supernus Pharmaceuticals by 3.6% during the second quarter. Commonwealth Equity Services LLC now owns 10,195 shares of the specialty pharmaceutical company’s stock worth $273,000 after acquiring an additional 350 shares in the last quarter.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 125,000 shares of the company’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the sale, the chief executive officer now directly owns 926,172 shares of the company’s stock, valued at approximately $33,971,988.96. This represents a 11.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Georges Gemayel sold 14,213 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.62, for a total transaction of $520,480.06. Following the completion of the transaction, the director now directly owns 13,315 shares of the company’s stock, valued at approximately $487,595.30. This trade represents a 51.63 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 154,213 shares of company stock valued at $5,660,180. Insiders own 9.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on SUPN. Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Cowen reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Supernus Pharmaceuticals Stock Up 0.5 %

Shares of SUPN stock opened at $35.59 on Tuesday. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.53 and a 12 month high of $39.37. The company’s fifty day simple moving average is $35.65 and its 200-day simple moving average is $32.28. The firm has a market cap of $1.97 billion, a PE ratio of 33.26 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, topping the consensus estimate of $0.44 by $0.25. The firm had revenue of $175.70 million for the quarter, compared to analysts’ expectations of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The company’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.29) EPS. On average, equities analysts predict that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.